Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (505)	11/3/2005 6:50:33 PM
From: keokalani'nui	Respond to of 590

Can't exactly recall, but I think 100% patients progressed at 8 weeks.

To: Miljenko Zuanic who wrote (505)	11/3/2005 6:50:57 PM
From: DewDiligence_on_SI	Read Replies (1) \| Respond to of 590

So many posts, and I still do not see numbers for TTP? PFS, not TTP, was the primary endpoint. In practice, TTP and PFS are nearly identical, the only difference being from very early deaths caused by treatment toxicity or some unrelated event (e.g. a car accident). The FDA prefers PFS rather than TTP just in case there are unexpected toxicities. 46% of what number? If the “tumor progression rate” was slowed by 46% in the Pani arm relative to the placebo arm (as was reported today), it means that PFS was lengthened by 46%, i.e. that there is 46% more area under the PFS Kaplan-Meier curve for the Pani arm than there is under the PFS Kaplan-Meier curve for the control arm.